|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA therapy.
|
29262549 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we aimed to estimate the results of PSMA-RLT in terms of response, progression-free survival (PFS), and overall survival (OS) in patients receiving a highly standardized treatment regimen due to mCRPC.
|
31781834 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on these promising preclinical results, <sup>152</sup>Tb was shipped to Zentralklinik Bad Berka, Germany, where it was used for labeling of PSMA-617, enabling PET imaging of a patient with mCRPC.
|
31346796 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the use of PSMA tracers in systemic radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC), as well as non-prostatic specific uptake of PSMA tracers and the use of PSMA imaging to manage therapy have been described.
|
28217987 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
|
31742767 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PATIENT SUMMARY: We analyzed the treatment outcome and toxicity of prostate-specific membrane antigen-targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer.
|
30473431 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single-agent PSMA-targeted radioligand therapy (PRLT) with the alpha-emitter <sup>225</sup>Ac showed promise against mCRPC but may cause severe and/or persistent xerostomia, which may substantially impair patients' quality-of-life.
|
31758224 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC).
|
31831560 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
|
29026946 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
|
30036254 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent years have seen the start of treatment of metastatic castration-resistant prostate cancer with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT), especially <sup>177</sup>Lu-PSMA-617.
|
30850503 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oligoarginine sequences conjugated to a short cancer-targeting peptide (CTP) selective for the prostate-specific membrane antigen (PSMA) receptor was developed for selective small interfering RNA (siRNA) delivery to a human metastatic/castration-resistant prostate cancer (PCa) cell line, which expresses PSMA on the surface.
|
31739211 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
With recent developments in PSMA-targeted radiopharmaceuticals, PSMA RLT agents are now under investigation for the treatment of mCRPC.
|
31353876 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
|
31789908 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the safety, efficacy, and effect on quality of life of [<sup>177</sup>Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments.
|
29752180 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent successes in the treatment of metastatic castration-resistant prostate cancer (mCRPCa) by systemic endoradiotherapy has sparked renewed interest in developing small molecule ligands targeting prostate-specific membrane antigen (PSMA) and chelators capable of stable complexation of metal radionuclides for imaging and therapy.
|
29055836 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).Fifteen patients each received two cycles of 3.7 GBq (n = 5) or 6.0 GBq (n = 10) 177Lu-PSMA-617 at an eight to ten weeks interval.
|
27683041 |
2017 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.
|
31693627 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a meta-analysis on the therapeutic effects of prostate-specific membrane antigen (PSMA)-617 labeled with lutetium-177 (Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC).
|
30059428 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this first-in-man dose-escalation study, PSMA ADC was administered by intravenous infusion every three weeks to subjects with progressive metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel chemotherapy.
|
30663074 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using <sup>177</sup>Lu-labeled PSMA ligands.
|
29873291 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney.
|
30829871 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA PET/CT for monitoring response to <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
|
30697649 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the safety and efficacy of BIND-014, a PSMA-directed docetaxel-containing nanoparticle, in patients with metastatic castration-resistant prostate cancer (mCRPC).
|
29978216 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup> Ga-PSMA PET/CT shows more lesions than bone scans, but data on diagnostic performance are very limited and indicate improved diagnostic performance in primary staging but not in mCRPC.
|
29082604 |
2017 |